Provide report on stocks of rare genetic blood disorder injection: Delhi HC asks Centre, Delhi govt

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-12-02T13:30:55+05:30 | Updated On 2 Dec 2024 1:30 PM IST

Cough Syrup Warning Will Not Affect Existing Stock: HC Relief to Glenmark, Zuventus

New Delhi: In response to the plea filed by several individuals suffering from haemophilia disease, the Delhi High Court has directed the Centre and Delhi government to file their reports on the status of stocks of Antihemophilic Factor injection.

The governments have also been asked to also provide status reports on the existing supply chain system for all the hospitals under their administration. The court listed the matter on December 12, PTI reported.

"The respondents are directed to file status reports with respect to the stock of the AHF injections, and the existing supply chain system for all the hospitals under their administration. The same be done within ten days," Justice Sanjeev Narula said in an order passed on November 28.

Read also: Weekly Efanesoctocog Alfa effective option for Preventing Bleeding among kids with Severe Hemophilia A: NEJM

The court was hearing a petition by several persons suffering from haemophilia disease.

The petitioners submitted that the treatment for this disease is expensive and requires injections of Antihemophilic Factor (AHF).

Read also: Pfizer's HYMPAVZI gets European Commission Approval to Treat Severe Hemophilia A and B

They said while the treatment for haemophilia is provided in the government hospitals, often there is insufficient stock of the injection which renders their lives at risk.

The plea sought a direction to the Centre and Delhi government to monitor the supply chain management of AHF injections in order to prevent any failure or stoppage in its supply and to develop contingency plans for critical shortage of the medication.

Haemophilia is a rare genetic blood disorder that impairs the blood's ability to clot properly, leading to excessive bleeding even from minor injuries. It is caused by a deficiency in certain clotting factors, which are proteins that help blood clot. Hemophilia is inherited and is most commonly seen in males.

delhi high courtantihemophilic factor injectionblood disorderhaemophilia

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751